ArticleMultiple sclerosis journal - experimental, translational and clinical
Cannabinoid use among Americans with MS: Current trends and gaps in knowledge.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis.Addiction (Abingdon, England) · 2026Pooled it
- Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis.Cannabis and cannabinoid research · 2023Pooled it
- Relationships between childhood trauma and multiple sclerosis: A systematic review.Journal of psychosomatic research · 2022Pooled it
- Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis.Archives of physical medicine and rehabilitation · 2026Article
- Temporal Association Between Reported Use of Psychoactive Substances and Cognitive Function in Individuals With Multiple Sclerosis.Archives of physical medicine and rehabilitation · 2026Article
- Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple Sclerosis.Current neuropharmacology · 2025Review
- Resilience, Mental Health, Sleep, and Smoking Mediate Pathways Between Lifetime Stressors and Multiple Sclerosis Severity.Sclerosis · 2024Article
- Resilience, mental health, sleep, and smoking mediate pathways between lifetime stressors and Multiple Sclerosis severity.medRxiv : the preprint server for health sciences · 2024Article
- Lifetime stressors relate to invisible symptoms of multiple sclerosis.Exploration of neuroprotective therapy · 2024Article
- Fatigue, pain interference, and psychiatric morbidity in multiple sclerosis: The role of childhood stress.PloS one · 2023Article
- Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living With Multiple Sclerosis.Neurology. Clinical practice · 2022Article
- Review
- Cannabis Use among Older Persons with Arthritis, Cancer and Multiple Sclerosis: Are We Comparing Apples and Oranges?Brain sciences · 2021Article
- A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis.International journal of MS careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUp-to-date information regarding the scope and impact of cannabinoid use among persons with MS (PwMS) is necessary to guide clinical practice and cannabinoid research.
objectivesTo assess utilization patterns and perceived impact of cannabinoid use among a national cohort of PwMS.
methodsData collected were part of a nationwide survey to characterize pain in PwMS. Items included questions about current/recent cannabinoid use, reasons for use, preferred THC/CBD formulations, and perceived benefits/side effects. PROMIS short-forms assessed symptom severity. Pain phenotype was assessed with the painDETECT questionnaire and FMSurvey Criteria Questionnaires.
resultsAmong n = 1,027 respondents, 42% endorsed recent cannabinoid use, of which 18% endorsed healthcare provider guidance regarding use. PROMIS scores (except cognitive abilities), and pain centralization and neuropathic pain scores, were higher among recent/current users (each p < 0.0001). Sleep and pain were the most frequently reported reasons for use. Benefit from cannabinoids for sleep and pain were strongly correlated (r = 0.65, p < 0.0001). For those who expressed a preference for specific THC/CBD ratios, CBD-predominant formulations were favored.
conclusionCannabinoid use is common in PwMS, despite a paucity of provider guidance. The range of perceived benefits, and potential differential effects of THC and CBD, highlight the need for personalized, evidence-based guidelines regarding cannabinoid use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.